About
OurCrowd is a global investment platform bringing venture capital opportunities to accredited investors worldwide. It is managed by a team of seasoned investment professionals and led by serial entrepreneur, Jon Medved.
OurCrowd vets and selects companies, invests its own capital, and invites its accredited membership of investors and institutional partners to invest alongside in these opportunities. OurCrowd provides support to its portfolio companies, assigns industry experts as mentors, and creates growth opportunities through its network of strategic multinational partnerships.
With $2.2 billion of committed funding, and investments in more than 420 portfolio companies and 50 venture funds, OurCrowd offers access to its membership of over 225,000 individual accredited and institutional investors, family offices, and venture capital partners from over 195 countries to invest alongside, at the same terms.
OurCrowd is headquartered in Jerusalem, with additional offices in Tel Aviv, New York, Abu Dhabi, Chicago, Hong Kong, London, Madrid, San Diego, São Paulo, Singapore, Toronto and Sydney.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is OurCrowd's total committed funding and number of portfolio companies?
- OurCrowd has $2.2 billion of committed funding and has invested in more than 420 portfolio companies and 50 venture funds.
- Which sectors does OurCrowd primarily focus on for investments?
- OurCrowd shows a strong focus on Health Tech & Life Sciences with 56 portfolio companies and Business Software with 51 portfolio companies.
- Has OurCrowd been recognized as a leading investor in Israel?
- Yes, OurCrowd was ranked as Israel's most active VC by Pitchbook in October 2021, August 2018, and March 2019.
- What notable funds has OurCrowd launched recently?
- In June 2024, OurCrowd established a new $80 million Israel-Korea fund for DeepTech investments. In August 2022, OurCrowd launched a $30 million FoodTech investment fund, and in September 2022, a $200 million global health equity fund in collaboration with the WHO Foundation.
- What is OurCrowd's strategy regarding early-stage investments?
- In February 2020, OurCrowd announced it would re-focus and intensify its incubator and early-stage investment activities, aiming to up its focus on the 'huge potential' of overlooked early-stage firms.
- What significant exits has OurCrowd seen in recent years?
- OurCrowd has seen several notable exits, including the acquisition of BioCatch by Permira for $750M in May 2024, and Innovalve Bio Medical by Edwards Lifesciences for $300M in July 2024. For a full list of exits, please refer to startupim data.
- How has OurCrowd expanded its international presence and partnerships?
- OurCrowd has expanded significantly, becoming the first Israeli VC firm to operate in Abu Dhabi Global Market in November 2021, and forming partnerships with entities like Japan's NTT Finance in March 2021, and leading a Uruguay accelerator consortium in March 2024.
- What is OurCrowd's approach to investing in war-affected startups in Israel?
- OurCrowd announced in December 2023 its plan to invest $50 million in Israeli startups impacted by the war, and further expanded this investment in March 2024.
- What is OurCrowd's involvement in the AI sector?
- OurCrowd has a strong focus on AI, launching an AI fund in March 2024 to fast-track startups into Nvidia's program and aiming to triple its head count at its Abu Dhabi AI office as of September 2023.